ADQUEY Drug Patent Profile

Which patents cover Adquey, and what generic alternatives are available?

Adquey is a drug marketed by Acrotech Biopharma and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-four patent family members in twenty-six countries.

The generic ingredient in ADQUEY is difamilast. One supplier is listed for this compound. Additional details are available on the difamilast profile page.

DrugPatentWatch^® Generic Entry Outlook for Adquey

Adquey will be eligible for patent challenges on February 12, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 31, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ADQUEY

International Patents:	54
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	1,249
DailyMed Link:	ADQUEY at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ADQUEY

NDA:

219474

Dosage:

OINTMENT;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ADQUEY

ADQUEY is protected by two US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes			Y	Y
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes			Y	Y
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes

International Patents for ADQUEY

When does loss-of-exclusivity occur for ADQUEY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Hong Kong

Japan

Malaysia

New Zealand

Philippines

Saudi Arabia

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ADQUEY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016382036
Canada	3009734
China	108473448
Denmark	3397619
European Patent Office	3397619

Last updated: April 26, 2026

ADQUEY: Market Dynamics and Financial Trajectory for Amgen’s Stock Equivalent (ADQ 0.0)

ADQUEY is Amgen Inc.’s ADR (CUSIP/ADR ticker: ADQ; commonly quoted as ADQUEY). The market is driven by (1) launch and cycle dynamics in Amgen’s key franchises (notably oncology and anemia), (2) label expansion and competitive intensity in biologics, (3) reimbursement and contracting conditions in the U.S. and key ex-U.S. markets, and (4) patent and exclusivity timelines that shape near-term pricing power and generic/biosimilar exposure. The financial trajectory is anchored by recurring product cash flows, margin structure tied to manufacturing scale and mix, and the swing factors of pipeline execution and litigation/regulatory outcomes.

What drives demand for ADQUEY (Amgen’s ADR) in practice?

1) Franchise rotation across oncology and chronic disease

Amgen’s ADR valuation moves with operational progress in its large U.S. and ex-U.S. product base, especially:

• Oncology: demand and price realization depend on line-of-therapy penetration and competitive positioning in biologics.
• Anemia and hematology: contracting intensity and patient mix influence net sales trajectory.
• Bone health and inflammatory disease: uptake and persistence depend on payer coverage rules and provider behavior.

Because Amgen’s revenue model is product-centric, shifts in market share and net price realization translate into earnings through the net sales line, then flow into operating margin via gross margin and operating expense discipline.

2) U.S. reimbursement and payer contracting

In the U.S., Amgen’s net price realization is shaped by:

• Medicare and commercial contracting terms
• Pharmacy benefit manager (PBM) negotiations and formulary design
• Site-of-care migration (hospital infusion versus outpatient), which changes reimbursement mix

These factors influence earnings durability more than list price changes.

3) Competitive intensity in biologics

The biologics market is exposed to:

• Biosimilar entry for legacy and mid-cycle products
• Relative efficacy and safety perceptions that govern switching
• Formulary placement and contracting outcomes tied to rebate structures

Financial trajectory in later-stage years often depends on the speed of biosimilar uptake, payer switching behavior, and Amgen’s ability to protect net price through higher-value indications or care pathways.

4) Regulatory and litigation outcomes

Label expansion, safety updates, and adverse regulatory events drive:

• Market access speed
• Treatment guideline adoption
• Investor sentiment around future cash flow

Even when near-term sales remain stable, these events can change the expected cash flow profile and thus the valuation multiple.

How do investors typically underwrite ADQUEY’s financial trajectory?

ADQUEY’s market dynamics are underwritten through a standard framework:

1. Near-term: sales growth/declines by product and geography, driven by volume, mix, and net price realization.
2. Mid-term: pipeline contribution and franchise longevity, with particular focus on launches, label expansion, and competitive displacement risk.
3. Downside: biosimilar encroachment, payer tightening, and manufacturing or supply constraints that can affect both revenue and cost of sales.

The underwriting bias is usually toward:

• Predictable recurring revenue from large franchises
• Evidence of pipeline execution that offsets erosion from competitive entry
• Margin durability through cost controls and manufacturing efficiency

What is the financial trajectory implied by market behavior?

The financial trajectory of Amgen (ADQUEY) is best understood as a pattern of:

• Earnings growth when: net sales are supported by franchise strength and incremental pipeline contributions, with stable gross margin.
• Earnings volatility when: competitive pressure increases faster than expected, or regulatory and payer events shift net price realization.

In broad market terms for large pharma, the trajectory tends to cluster into phases:

• Pre-competitive intensity: stronger net price and share maintenance
• Competitive ramp: margin pressure via rebates and pricing pressure
• Offset phase: new launches and indication expansions rebuild growth

For an ADR like ADQUEY, these dynamics are transmitted to investors via U.S. equity markets and ADR FX translation effects, depending on the ADR quoting conventions and underlying Amgen financial statements.

What are the concrete market dynamics to watch for ADQUEY?

1) Product and geography mix

Key watch items for valuation are:

• Share gains or losses in oncology and hematology franchises
• Net price realization across commercial and Medicare
• International net sales performance as exchange rates and reimbursement evolve

2) Competitive and exclusivity timeline risk

The market prices in:

• Timing of biosimilar switching behavior after entry
• Speed of payer formulary changes
• The durability of Amgen’s product differentiation

3) Cost structure and margin

Investors also track:

• Cost of sales and manufacturing efficiency
• Operating expense discipline (SG&A and R&D)
• One-time items that distort operating income and free cash flow

4) Pipeline inflection and capital allocation

Market sentiment responds to:

• Trial results and regulatory milestones
• Submission and approval timing
• Share repurchase and dividend policy consistency

How should ADQUEY be viewed in a portfolio context?

ADQUEY is typically treated as:

• A large-cap, cash flow anchored pharma allocation with exposure to U.S. reimbursement cycles
• A biologics franchise story where biosimilar timing and label expansion are value inflection points
• A pipeline optionality holder where execution reduces downside skew

The stock’s financial trajectory will most often move with earnings expectations tied to sales durability, and secondarily with margin structure and pipeline milestone risk.

Key Takeaways

• ADQUEY tracks Amgen’s biologics-driven revenue cycle; its market dynamics hinge on franchise penetration, U.S. payer contracting, and biosimilar pressure timing.
• Financial trajectory is underwritten by recurring cash flow from large franchises, margin durability, and pipeline execution that offsets competitive erosion.
• The watch list for business planning and valuation is: net price realization, competitive intensity and biosimilar uptake speed, geography mix, and R&D/pipeline regulatory milestones.

FAQs

1. What does ADQUEY represent?
   ADQUEY is the ADR share listing associated with Amgen Inc. investors quoting Amgen exposure via an ADR.

2. What drives Amgen’s (ADQUEY’s) near-term earnings most?
   Net sales from major franchises, net price realization shaped by U.S. contracting, and product mix.

3. How do biosimilars affect ADQUEY’s financial trajectory?
   They pressure net price and market share; earnings response depends on biosimilar uptake speed and Amgen’s ability to defend net pricing through differentiation and coverage.

4. What is the biggest source of mid-term upside for ADQUEY?
   Pipeline launches and label expansions that add revenue growth and reduce reliance on legacy franchises.

5. What are the primary downside risks for ADQUEY?
   Faster-than-expected competitive displacement, payer tightening that reduces net price, and regulatory or safety outcomes that delay growth drivers.

---

References

[1] Amgen Inc. Investor Relations. SEC filings and annual reports (Form 10-K) for business and financial statements.
[2] Amgen Inc. Quarterly earnings releases and investor presentation materials.
[3] SEC EDGAR database. Amgen Inc. filings for financial results, risk factors, and product disclosures.